Treatment  ||| S:0 E:10 ||| NN
of  ||| S:10 E:13 ||| IN
multiple  ||| S:13 E:22 ||| JJ
sclerosis  ||| S:22 E:32 ||| NN
and  ||| S:32 E:36 ||| CC
neuromyelitis  ||| S:36 E:50 ||| JJ
optica  ||| S:50 E:57 ||| NN
in  ||| S:57 E:60 ||| IN
children  ||| S:60 E:69 ||| NNS
and  ||| S:69 E:73 ||| CC
adolescents  ||| S:73 E:85 ||| FW
Paediatric  ||| S:85 E:96 ||| FW
multiple  ||| S:96 E:105 ||| FW
sclerosis  ||| S:105 E:115 ||| FW
( ||| S:115 E:116 ||| -LRB-
MS ||| S:116 E:118 ||| NNP
)  ||| S:118 E:120 ||| -RRB-
accounts  ||| S:120 E:129 ||| NNS
for  ||| S:129 E:133 ||| IN
up  ||| S:133 E:136 ||| RB
to  ||| S:136 E:139 ||| TO
5 ||| S:139 E:140 ||| CD
%  ||| S:140 E:142 ||| NN
of  ||| S:142 E:145 ||| IN
all  ||| S:145 E:149 ||| DT
MS  ||| S:149 E:152 ||| NNP
cases ||| S:152 E:157 ||| NNS
.  ||| S:157 E:159 ||| .
No  ||| S:159 E:162 ||| DT
therapies  ||| S:162 E:172 ||| NNS
have  ||| S:172 E:177 ||| VBP
been  ||| S:177 E:182 ||| VBN
formally  ||| S:182 E:191 ||| RB
approved  ||| S:191 E:200 ||| VBN
for  ||| S:200 E:204 ||| IN
paediatric  ||| S:204 E:215 ||| JJ
patients  ||| S:215 E:224 ||| NNS
with  ||| S:224 E:229 ||| IN
MS ||| S:229 E:231 ||| NNP
.  ||| S:231 E:233 ||| .
However ||| S:233 E:240 ||| RB
,  ||| S:240 E:242 ||| ,
there  ||| S:242 E:248 ||| EX
is  ||| S:248 E:251 ||| VBZ
published  ||| S:251 E:261 ||| VBN
experience  ||| S:261 E:272 ||| NN
on  ||| S:272 E:275 ||| IN
the  ||| S:275 E:279 ||| DT
use  ||| S:279 E:283 ||| NN
of  ||| S:283 E:286 ||| IN
disease  ||| S:286 E:294 ||| NN
modifying  ||| S:294 E:304 ||| NN
therapies  ||| S:304 E:314 ||| NNS
in  ||| S:314 E:317 ||| IN
children  ||| S:317 E:326 ||| NNS
and  ||| S:326 E:330 ||| CC
adolescents  ||| S:330 E:342 ||| NNS
with  ||| S:342 E:347 ||| IN
MS ||| S:347 E:349 ||| NNP
.  ||| S:349 E:351 ||| .
Neuromyelitis  ||| S:351 E:365 ||| JJ
optica  ||| S:365 E:372 ||| NNS
( ||| S:372 E:373 ||| -LRB-
NMO ||| S:373 E:376 ||| NNP
)  ||| S:376 E:378 ||| -RRB-
is  ||| S:378 E:381 ||| VBZ
an  ||| S:381 E:384 ||| DT
autoimmune  ||| S:384 E:395 ||| JJ
inflammatory  ||| S:395 E:408 ||| JJ
disease  ||| S:408 E:416 ||| NN
preferentially  ||| S:416 E:431 ||| VBZ
targeting  ||| S:431 E:441 ||| VBG
the  ||| S:441 E:445 ||| DT
optic  ||| S:445 E:451 ||| JJ
nerves  ||| S:451 E:458 ||| NNS
and  ||| S:458 E:462 ||| CC
spinal  ||| S:462 E:469 ||| JJ
cord ||| S:469 E:473 ||| NN
.  ||| S:473 E:475 ||| .
This  ||| S:475 E:480 ||| DT
devastating  ||| S:480 E:492 ||| JJ
disease  ||| S:492 E:500 ||| NN
usually  ||| S:500 E:508 ||| RB
requires  ||| S:508 E:517 ||| VBZ
preventive  ||| S:517 E:528 ||| JJ
therapy  ||| S:528 E:536 ||| NN
with  ||| S:536 E:541 ||| IN
a  ||| S:541 E:543 ||| DT
range  ||| S:543 E:549 ||| NN
of  ||| S:549 E:552 ||| IN
immunosuppressive  ||| S:552 E:570 ||| JJ
medications ||| S:570 E:581 ||| NN
.  ||| S:581 E:583 ||| .
There  ||| S:583 E:589 ||| EX
are  ||| S:589 E:593 ||| VBP
limited  ||| S:593 E:601 ||| JJ
studies  ||| S:601 E:609 ||| NNS
informing  ||| S:609 E:619 ||| VBG
the  ||| S:619 E:623 ||| DT
use  ||| S:623 E:627 ||| NN
of  ||| S:627 E:630 ||| IN
these  ||| S:630 E:636 ||| DT
medications  ||| S:636 E:648 ||| NN
in  ||| S:648 E:651 ||| IN
children  ||| S:651 E:660 ||| NNS
with  ||| S:660 E:665 ||| IN
NMO ||| S:665 E:668 ||| NNP
.  ||| S:668 E:670 ||| .
This  ||| S:670 E:675 ||| DT
review  ||| S:675 E:682 ||| NN
provides  ||| S:682 E:691 ||| VBZ
a  ||| S:691 E:693 ||| DT
comprehensive  ||| S:693 E:707 ||| JJ
analysis  ||| S:707 E:716 ||| NN
of  ||| S:716 E:719 ||| IN
the  ||| S:719 E:723 ||| DT
published  ||| S:723 E:733 ||| JJ
literature  ||| S:733 E:744 ||| NN
on  ||| S:744 E:747 ||| IN
therapeutic  ||| S:747 E:759 ||| JJ
interventions  ||| S:759 E:773 ||| NNS
in  ||| S:773 E:776 ||| IN
children  ||| S:776 E:785 ||| NNS
and  ||| S:785 E:789 ||| CC
adolescents  ||| S:789 E:801 ||| NNS
with  ||| S:801 E:806 ||| IN
MS  ||| S:806 E:809 ||| NNP
and  ||| S:809 E:813 ||| CC
NMO ||| S:813 E:816 ||| NNP
.  ||| S:816 E:818 ||| .
